T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| 1 |
Broadcom
AVGO
|
+$3.01B |
| 2 |
Gilead Sciences
GILD
|
+$1.25B |
| 3 |
Accenture
ACN
|
+$1.09B |
| 4 |
XYZ
Block, Inc.
XYZ
|
+$1.06B |
| 5 |
Valero Energy
VLO
|
+$1.05B |
Top Sells
| 1 |
NVIDIA
NVDA
|
+$3.94B |
| 2 |
Meta Platforms (Facebook)
META
|
+$1.84B |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$1.47B |
| 4 |
Eli Lilly
LLY
|
+$1.43B |
| 5 |
Tesla
TSLA
|
+$1.4B |
Sector Composition
| 1 | Technology | 30.49% |
| 2 | Healthcare | 13.92% |
| 3 | Financials | 12.27% |
| 4 | Consumer Discretionary | 10.96% |
| 5 | Communication Services | 9.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
901
Ball Corp
BALL
$13.6B
| $24.1M | ﹤0.01% |
462,896
-2,467,915
| -84% | -$129M |
|
902
Mueller Industries
MLI
$10.9B
| $24.1M | ﹤0.01% |
316,464
+5,640
| +2% | +$429K |
|
903
SLM Corp
SLM
$5.81B
| $24.1M | ﹤0.01% |
819,306
-11,702
| -1% | -$344K |
|
904
ASGN Inc
ASGN
$2.24B
| $24M | ﹤0.01% |
381,565
+12,757
| +3% | +$804K |
|
|
PRMB
905
Primo Brands Corporation
PRMB
$8.38B
| $24M | ﹤0.01% |
676,960
+331,222
| +96% | +$11.8M |
|
906
LeMaitre Vascular
LMAT
$2.09B
| $24M | ﹤0.01% |
285,735
+956
| +0.3% | +$80.2K |
|
907
PTC Therapeutics
PTCT
$4.69B
| $23.9M | ﹤0.01% |
468,554
-40,650
| -8% | -$2.07M |
|
908
Akamai
AKAM
$11B
| $23.8M | ﹤0.01% |
296,033
+1,224
| +0.4% | +$98.5K |
|
909
Trimble
TRMB
$19.3B
| $23.8M | ﹤0.01% |
362,331
+8,686
| +2% | +$570K |
|
910
Catalyst Pharmaceutical
CPRX
$2.42B
| $23.7M | ﹤0.01% |
977,623
-237,815
| -20% | -$5.77M |
|
911
Coherent
COHR
$16.6B
| $23.6M | ﹤0.01% |
362,776
-146,339
| -29% | -$9.5M |
|
912
Alliant Energy
LNT
$16.6B
| $23.5M | ﹤0.01% |
365,584
+5,236
| +1% | +$337K |
|
|
BCAX
913
Bicara Therapeutics Inc. Common Stock
BCAX
$621M
| $23.4M | ﹤0.01% |
1,798,021
+250,841
| +16% | +$3.27M |
|
914
Kohl's
KSS
$1.8B
| $23.4M | ﹤0.01% |
2,855,659
-2,058,471
| -42% | -$16.8M |
|
915
Valvoline
VVV
$5.11B
| $23.3M | ﹤0.01% |
669,961
-19,765
| -3% | -$688K |
|
916
Vanguard FTSE Developed Markets ETF
VEA
$175B
| $23.3M | ﹤0.01% |
+45,777
| New | +$23.3M |
|
917
Evertec
EVTC
$2.12B
| $23.2M | ﹤0.01% |
631,877
+4,056
| +0.6% | +$149K |
|
918
Hologic
HOLX
$14.2B
| $23M | ﹤0.01% |
373,091
-856,764
| -70% | -$52.9M |
|
919
Dycom Industries
DY
$7.4B
| $22.9M | ﹤0.01% |
150,435
+1,556
| +1% | +$237K |
|
920
Viridian Therapeutics
VRDN
$1.47B
| $22.8M | ﹤0.01% |
1,688,129
+361,318
| +27% | +$4.87M |
|
921
Synaptics
SYNA
$2.73B
| $22.7M | ﹤0.01% |
356,315
+328,037
| +1,160% | +$20.9M |
|
922
Haemonetics
HAE
$2.47B
| $22.7M | ﹤0.01% |
357,182
+2,901
| +0.8% | +$184K |
|
923
Addus HomeCare
ADUS
$2.01B
| $22.5M | ﹤0.01% |
227,058
+422
| +0.2% | +$41.7K |
|
924
UMB Financial
UMBF
$9.14B
| $22.3M | ﹤0.01% |
220,939
+65,806
| +42% | +$6.65M |
|
925
Travel + Leisure Co
TNL
$4.01B
| $22.3M | ﹤0.01% |
482,235
+26,744
| +6% | +$1.24M |
|